Compare Strategy Inc. (MSTR) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Strategy Inc. vs Twist Bioscience Corp — how do they compare? Strategy Inc. trades at $133.49 (market cap $54.24B), while Twist Bioscience Corp trades at $125.52 (market cap $8.42B). The key difference: Strategy Inc. is far larger — about 6.4× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Strategy Inc. nearer its low. Which is the better fit depends on your goals.
| MSTR | TWST | |
|---|---|---|
Market Cap | $54.24B | $8.42B |
Sector | Technology | Health |
52-Week High | $359.69 | $153.10 |
52-Week Low | $82.31 | $24.16 |
Enterprise Value | $73.00B | $8.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTR trades at $136.52, down 4.4% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of -$24.45, missing estimates, and has a negative net income margin of -6,102.96%. Recent news highlights a $176.3 million preferred stock buyback instead of Bitcoin purchases, and a partnership with Google Cloud for an AI forum series.
The outlook is mixed: analyst consensus is bullish with a $229.64 price target, but significant risks include persistent earnings misses, high debt, and negative profitability. The stock's performance is heavily tied to Bitcoin market sentiment, posing volatility risks despite institutional interest.
Twist Bioscience (TWST) trades at $128.06, up 2.68% today, but remains below the analyst consensus price target of $106.14. The stock shows mixed technical signals with bearish overall momentum but bullish moving averages. Fundamentally, the company continues to report losses with a net income margin of -31.66% despite 23% revenue growth in Q3 2026. Recent news highlights AI-driven optimism and institutional buying interest.
TWST presents a high-risk growth story with strong analyst support (79% buy ratings) but persistent profitability challenges. The stock's valuation appears stretched with P/S of 18.09 and P/B of 18.89. Key catalysts include AI drug discovery partnerships and path to EBITDA breakeven, while risks include cash burn and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
